Atossa Therapeutics
ATOS
84 hedge funds and large institutions have $17.7M invested in Atossa Therapeutics in 2025 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 14 increasing their positions, 23 reducing their positions, and 28 closing their positions.
91% more call options, than puts
Call options by funds: $174K | Put options by funds: $91K
1% more funds holding
Funds holding: 83 → 84 (+1)
4% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 28
0.36% less ownership
Funds ownership: 1.46% → 1.1% (-0.36%)
7% less capital invested
Capital invested by funds: $19.1M → $17.7M (-$1.36M)
39% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
+$2.37M |
| 2 |
Millennium Management
New York
|
+$1.63M |
| 3 |
Jane Street
New York
|
+$366K |
| 4 |
YIH
Y-Intercept (HK)
Hong Kong
|
+$308K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$259K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$5.96M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$1.23M |
| 3 |
State Street
Boston,
Massachusetts
|
-$965K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$600K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$566K |
ATOS Hedge Fund Activity: Q2 2025 in Review
84 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Atossa Therapeutics (ATOS) for Q2 2025, worth a combined $17.7M — down 7.2% from $19.1M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new ATOS positions and 28 closed out — a net gain of 1 holder — while 14 added to existing stakes and 23 trimmed.
The largest buyer was Ameriprise, opening a new position worth an estimated $2.37M. The largest seller was BlackRock, cutting an estimated $5.96M.
- 84 institutional investors held Atossa Therapeutics (ATOS) as of Q2 2025, up from 83 in Q1 2025.
- Funds reported $17.7M of Atossa Therapeutics stock for Q2 2025, down 7.2% quarter-over-quarter.
- 29 funds opened new Atossa Therapeutics positions in Q2 2025 and 28 closed out, a net change of +1 holder.
- The largest Atossa Therapeutics buyer in Q2 2025 was Ameriprise, an estimated $2.37M added.
- The largest Atossa Therapeutics seller in Q2 2025 was BlackRock, an estimated $5.96M sold.
Based on aggregated 13F filings for Q2 2025.